Clearpoint Neuro IncNASDAQ:CLPT
- LAST PRICE6.4000
- TODAY'S CHANGE (%)0.3900 (6.4892%)
- Bid / Lots6.2000/ 1
- Ask / Lots6.9400/ 1
- Open / Previous Close6.0500 / 6.0100
- Day Range
- 52 Week Range
- Volume190,975
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLPT |
|---|---|---|
| 09:32 ET | 746 | 6.05 |
| 09:36 ET | 1099 | 6.14 |
| 09:39 ET | 1509 | 6.05 |
| 09:41 ET | 200 | 6.05 |
| 09:52 ET | 220 | 6.1 |
| 09:54 ET | 300 | 6.1 |
| 09:56 ET | 1356 | 6.115 |
| 09:57 ET | 100 | 6.16 |
| 09:59 ET | 2550 | 6.1289 |
| 10:06 ET | 308 | 6.18 |
| 10:12 ET | 1000 | 6.18 |
| 10:14 ET | 19570 | 6.2 |
| 10:15 ET | 100 | 6.195 |
| 10:17 ET | 11010 | 6.28 |
| 10:19 ET | 200 | 6.28 |
| 10:21 ET | 700 | 6.27 |
| 10:24 ET | 100 | 6.2893 |
| 10:26 ET | 2815 | 6.34 |
| 10:28 ET | 6200 | 6.29 |
| 10:32 ET | 1100 | 6.3 |
| 10:33 ET | 2714 | 6.26 |
| 10:37 ET | 1226 | 6.275 |
| 10:39 ET | 317 | 6.31 |
| 10:46 ET | 200 | 6.31 |
| 10:48 ET | 3196 | 6.32 |
| 10:50 ET | 14311 | 6.395 |
| 10:51 ET | 4077 | 6.35 |
| 10:53 ET | 200 | 6.31 |
| 10:55 ET | 1712 | 6.24 |
| 10:57 ET | 4397 | 6.24 |
| 11:22 ET | 200 | 6.28 |
| 11:24 ET | 1949 | 6.3 |
| 11:31 ET | 400 | 6.31 |
| 11:33 ET | 1000 | 6.31 |
| 11:36 ET | 2000 | 6.34 |
| 11:42 ET | 200 | 6.335 |
| 11:44 ET | 400 | 6.32 |
| 11:45 ET | 1345 | 6.36 |
| 11:49 ET | 2600 | 6.36 |
| 11:56 ET | 2784 | 6.36 |
| 11:58 ET | 3450 | 6.38 |
| 12:00 ET | 2979 | 6.37 |
| 12:02 ET | 4938 | 6.2901 |
| 12:05 ET | 1000 | 6.29 |
| 12:12 ET | 200 | 6.325 |
| 12:18 ET | 250 | 6.3304 |
| 12:20 ET | 100 | 6.31 |
| 12:21 ET | 800 | 6.29 |
| 12:23 ET | 100 | 6.29 |
| 12:25 ET | 200 | 6.28 |
| 12:34 ET | 200 | 6.305 |
| 12:39 ET | 200 | 6.33 |
| 12:45 ET | 228 | 6.3173 |
| 12:52 ET | 100 | 6.35 |
| 12:59 ET | 400 | 6.35 |
| 01:01 ET | 100 | 6.355 |
| 01:06 ET | 200 | 6.355 |
| 01:08 ET | 100 | 6.35 |
| 01:12 ET | 2400 | 6.33 |
| 01:15 ET | 1100 | 6.35 |
| 01:17 ET | 300 | 6.36 |
| 01:21 ET | 300 | 6.36 |
| 01:24 ET | 2955 | 6.34 |
| 01:32 ET | 400 | 6.34 |
| 01:35 ET | 100 | 6.34 |
| 01:37 ET | 1437 | 6.315 |
| 01:42 ET | 2900 | 6.36 |
| 01:44 ET | 1300 | 6.35 |
| 01:46 ET | 486 | 6.35 |
| 01:48 ET | 215 | 6.3425 |
| 01:53 ET | 100 | 6.365 |
| 01:57 ET | 1200 | 6.36 |
| 02:00 ET | 100 | 6.365 |
| 02:02 ET | 100 | 6.365 |
| 02:04 ET | 300 | 6.36 |
| 02:08 ET | 1250 | 6.3401 |
| 02:09 ET | 200 | 6.365 |
| 02:13 ET | 100 | 6.34 |
| 02:15 ET | 300 | 6.36 |
| 02:18 ET | 1000 | 6.34 |
| 02:22 ET | 1148 | 6.34 |
| 02:26 ET | 2379 | 6.37 |
| 02:27 ET | 3400 | 6.356 |
| 02:29 ET | 100 | 6.34 |
| 02:31 ET | 740 | 6.3201 |
| 02:33 ET | 592 | 6.35 |
| 02:38 ET | 100 | 6.36 |
| 02:47 ET | 200 | 6.36 |
| 02:51 ET | 200 | 6.36 |
| 02:54 ET | 300 | 6.36 |
| 03:00 ET | 100 | 6.37 |
| 03:09 ET | 100 | 6.37 |
| 03:14 ET | 4151 | 6.35 |
| 03:16 ET | 300 | 6.37 |
| 03:20 ET | 641 | 6.385 |
| 03:21 ET | 1000 | 6.385 |
| 03:23 ET | 700 | 6.39 |
| 03:25 ET | 100 | 6.39 |
| 03:30 ET | 500 | 6.3967 |
| 03:32 ET | 1200 | 6.38 |
| 03:34 ET | 200 | 6.38 |
| 03:36 ET | 400 | 6.38 |
| 03:38 ET | 1172 | 6.37 |
| 03:45 ET | 100 | 6.375 |
| 03:48 ET | 200 | 6.38 |
| 03:52 ET | 100 | 6.37 |
| 03:54 ET | 1160 | 6.395 |
| 03:56 ET | 1164 | 6.41 |
| 03:57 ET | 1900 | 6.415 |
| 03:59 ET | 5195 | 6.4 |
May 7, 2024
ClearPoint Neuro Reports First Quarter 2024 Results, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones*DJ ClearPoint Neuro 1Q Loss/Shr 16c >CLPT, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
May 2, 2024
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore, from 4:05PM ET on Thursday May 02, 2024 by Dow Jones
4:05PM ET on Thursday May 02, 2024 by Dow JonesSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT), from 9:00AM ET on Thursday May 02, 2024 by Dow Jones
9:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 29, 2024
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clearpoint Neuro Inc | 164.8M | -7.7x | --- |
Stereotaxis Inc | 171.6M | -8.1x | --- |
Sensus Healthcare Inc | 86.9M | 21.5x | --- |
Olympus Corp | 18.9B | 110.3x | --- |
Orchestra Biomed Holdings Inc | 186.1M | -3.2x | --- |
Electromed Inc | 146.0M | 35.3x | +10.79% |
Company Information
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Contact Information
- Headquarters
- 120 S. SIERRA AVENUE, SUITE 100SOLANA BEACH, CA, United States 92075
- Phone
- 949-900-6833
- Fax
- 949-900-6834
Executives
- Independent Chairman of the Board
- R. John Fletcher
- President, Chief Executive Officer, Director
- Joseph Burnett
- Chief Financial Officer
- Danilo D' Alessandro
- Chief Operating Officer
- Mazin Sabra
- Chief Business Officer
- Jeremy Stigall
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $164.8M |
|---|---|
Revenue (TTM) | $26.2M |
Shares Outstanding | 27.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.07 |
EPS | $-0.83 |
Book Value | $0.86 |
P/E Ratio | -7.7x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -80.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
